FutureWise Market Research, a leading provider of market intelligence and strategic insights, has released an in-depth ...

The vaccine protects against the serotypes responsible for the majority of adult invasive pneumococcal disease ...

Merck’s Capvaxive receives European approval for prevention of invasive pneumococcal disease and pneumococcal pneumonia in adults: Rahway, New Jersey Friday, March 28, 2025, 09: ...

Infants with invasive group B Streptococcus disease had a 41% higher risk for psychiatric disorders than control individuals (adjusted hazard ratio [aHR], 1.41; 95% CI, 1.23-1.62), with the risk ...

The following is a summary of “Effect of probiotics on necrotizing enterocolitis in preterm infants: a network meta-analysis ...

The decision was influenced by the positive recommendation from the EMA’s Committee for Medicinal Products for Human Use.

Antibiotic-resistant bacteria are a serious public health threat. Understanding the biology of these bacteria—such as how ...

These findings demonstrate that the capsular serotype and genetic background significantly impact pneumococcal growth kinetics. The resultant growth features likely depend on the interaction between ...

The 24 pathogen families listed in the reference tool include microorganisms that cause Covid-19 and Nipah virus, among ...

Approves Merck’s CAPVAXIVE® (Pneumococcal 21-valent Conjugate Vaccine) for Prevention of Invasive Pneumococcal Disease and ...

The emergence of antibiotic-resistant strains threatens to set back the world a hundred years to the age when even a minor ...

Merck (MRK), known as MSD outside of the United States and Canada, announced that the European Commission, or EC, has approved CAPVAXIVE, or ...